mAbxience and Sandoz Partner on Hemophilia A Biosimilar

Under the terms of the agreement, mAbxience will manage the development and manufacturing of the biosimilar candidate at its GMP-certified facilities in Spain and Argentina. Sandoz will subsequently take charge of global commercialization, excluding the markets of Argentina, Uruguay, and Paraguay. While financial details remain private, the move reflects a broader industry shift as several biologic drugs approach the end of their exclusivity periods.

For mAbxience, the project marks a strategic entry into the rare disease sector. Hemophilia A, characterized by a deficiency in the blood-clotting protein factor VIII, accounts for 80% of all hemophilia cases globally. CEO Jurgen Van Broeck noted that the collaboration validates the company's platform, positioning it to address significant unmet medical needs through Sandoz’s established commercial infrastructure. The candidate adds to a growing portfolio that already includes treatments for oncology, immunology, and bone-related conditions.